Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q99720

UPID:
SGMR1_HUMAN

ALTERNATIVE NAMES:
Aging-associated gene 8 protein; SR31747-binding protein; Sigma 1-type opioid receptor

ALTERNATIVE UPACC:
Q99720; D3DRM7; O00673; O00725; Q0Z9W6; Q153Z1; Q2TSD1; Q53GN2; Q7Z653; Q8N7H3; Q9NYX0

BACKGROUND:
The Sigma non-opioid intracellular receptor 1, identified for its drug-binding capabilities, is integral to learning, memory, and mood regulation. It functions in lipid transport from the endoplasmic reticulum, influencing lipid microdomains at the plasma membrane, and plays a role in neurotransmitter release and calcium signaling. Its necessity for proper mitochondrial transport and cell survival against oxidative stress positions it as a key player in neuronal health.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in diseases such as Amyotrophic lateral sclerosis 16 and Distal spinal muscular atrophy, autosomal recessive, 2, Sigma non-opioid intracellular receptor 1 represents a promising target for therapeutic intervention. Its broad impact on cellular functions and disease association underscores the potential for developing treatments aimed at modulating its activity to combat neurodegenerative disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.